IRIS

Sfoglia per Titolo

Opzioni
Vai a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Mostrati risultati da 17.182 a 17.201 di 25.485
Titolo Data di pubblicazione Autore(i) File
Phase II study of everolimus in patients with thymoma and thymic carcinoma previously treated with cisplatin-based chemotherapy 1-gen-2018 Zucali, PAOLO ANDREA; De Pas, T; Palmieri, G; Favaretto, A; Chella, A; Tiseo, M; Caruso, M; Simonelli, M; Perrino, M; De Vincenzo, F; Toffalorio, F; Damiano, V; Pasello, G; Garbella, E; Ali, M; Conforti, F; Ottaviano, M; Cioffi, A; De Placido, S; Giordano, L; Bertossi, M; Destro, A; Di Tommaso, L; Santoro, A
Phase II study of hypofractionated radiation therapy in elderly patients with newly diagnosed glioblastoma with poor prognosis 1-gen-2019 Navarria, P; Pessina, F; Cozzi, L; Tomatis, S; Reggiori, G; Simonelli, M; Santoro, A; Clerici, E; Franzese, C; Carta, G; Nibali, Mc; Bello, L; Scorsetti, M
Phase II study of hypofractionated radiation therapy with concomitant and adjuvant Temozolomide following surgical resection for patients with newly diagnosed glioblastoma:preliminary evaluation 1-gen-2016 Navarria, P; Pessina, F; Ascolese, A; Tomatis, S; Bello, L; Simonelli, M; Riva, M; Lopci, E; Santoro, A; Scorsetti, M
Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancer 1-gen-2003 D'Agostino, G; Ferrandina, G; Ludovisi, M; Testa, A; Lorusso, D; Gbaguidi, N; Breda, E; Mancuso, S; Scambia, G
PHASE II STUDY OF LIPOSOMAL DOXORUBICIN AND GEMCITABINE IN THE TREATMENT OF RECURRENT OVARIAN CANCER 1-gen-2004 Ferrandina, G.; Paris, I.; D'Agostino, G.; Ludovisi, M.; Zanghi, M.; Lorusso, D; Testa, A. C.; Scandurra, G.; Pisconti, S.; Pezzella, G.; Adamo, V.; Scambia, G.
Phase II Study of Lutetium-177-labeled Anti Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. 1-gen-2015 Muselaers, Chj; Boers-Sonderen, Mj; van Oostenbrugge, Tj; Boerman, Oc; Desar, Ime; Stillebroer, Ab; Mulder, Sf; van Herpen, Cml; Langenhuijsen, Jf; Oosterwijk, E; Mulders, Pfa; Oyen, W
Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. 1-gen-2016 Muselaers, S; Boers-Sonderen, M; van Oostenbrugge, T; Boerman, O; Desar, I; Stillebroer, A; Mulder, S; van Herpen, C; Langenhuijsen, J; Oosterwijk, E; Oyen, W; Mulders, P
Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. 1-gen-2015 Boers-Sonderen, M; Muselaers, S; van Oostenbrugge, T; Boerman, O; Desar, I; Stillebroer, A; Mulder, S; Van Herpen, Cml; Langenhuijsen, H; Oosterwijk, E; Oyen, W; Mulders, P
Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients 1-gen-2012 Lorusso, D; Scambia, G.; Amadio, G.; di Legge, A.; Pietragalla, A.; De Vincenzo, R.; Masciullo, V.; Di Stefano, M.; Mangili, G.; Citterio, G.; Mantori, M.; Lambiase, A.; Bordignon, C.
Phase II Study of NGR-hTNF Plus Doxorubicin in Relapsed Ovarian Cancer (OC) 1-gen-2011 Lorusso, D; Scambia, G.; Amadio, G.; Trivellizzi, N.; Pietragalla, A.; De Vincenzo, R.; Salutari, V.; Di Stefano, M.; Lambiase, A.; Bordignon, C.
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy 1-gen-2010 Santoro, A; Rimassa, L; Sobrero, Af; Citterio, G; Sclafani, F; Carnaghi, C; Pessino, A; Caprioni, F; Andretta, V; Tronconi, Mc; Finocchiaro, G; Rossoni, G; Zanoni, A; Miggiano, C; Rizzardi, Gp; Traversari, C; Caligaris-Cappio, F; Lambiase, A; Bordignon, C
Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. 1-gen-1991 Wagener, D J; Somers, R; Santoro, A; Verweij, J; Woll, P J; Blackledge, G; Schutte, H J; Lentz, M A; van Glabbeke, M
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent ovarian cancer 1-gen-2006 Ferrandina, G.; Ludovisi, M.; D'Agostino, G.; Naldini, A.; Lorusso, D; Testa, A. C.; Legge, F.; Salutari, V.; Scambia, G.
Phase II study of oxaliplatin (OXA) and docetaxel (DTX) in recurrent platinum-sensitive ovarian cancer 1-gen-2004 Ferrandina, G; Ludovisi, M; Dagostino, G; Lorusso, D; Naldini, A; Testa, Ac; Paris, I; Gallotta, V; Pozzo, C; Scambia, G
Phase II study of pegylated liposomal doxorubicin in heavily pretreated epithelial ovarian cancer patients - May a new treatment schedule improve toxicity profile? 1-gen-2004 Lorusso, D; Naldini, A; Testa, A; D'Agostino, G; Scambia, G; Ferrandina, G
Phase II study of Pemetrexed and Carboplatin plus Bevacizumab as first-line therapy in malignant pleural mesothelioma 1-gen-2013 Ceresoli, G; Zucali, Pa; Mencoboni, M; Botta, M; Grossi, F; Cortinovis, D; Zilembo, N; Ripa, C; Tiseo, M; Favaretto, Ag; Soto-Parra, H; De Vincenzo, F; Bruzzone, A; Lorenzi, E; Gianoncelli, L; Ercoli, B; Giordano, L; Santoro, A
Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma 1-gen-2006 Ceresoli, Gl; Zucali, Pa; Favaretto, Ag; Grossi, F; Bidoli, P; Del Conte, G; Ceribelli, A; Bearz, A; Morenghi, E; Cavina, R; Marangolo, M; Parra, Hjs; Santoro, A
Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases 1-gen-2014 A., Guidetti; Carlo Stella, C.; S. L., Locatelli; W., Malorni; R., Mortarini; S., Viviani; D., Russo; A., Marchianò; R., Sorasio; A., Dodero; L., Farina; L., Giordano; M., Di Nicola; A., Anichini; P., Corradini; A. M., Gianni
Phase II study of preoperative TPF chemotherapy in molecularly selected resectable oral cavity cancer-Trial in progress 1-gen-2015 Bianchi, R; Bossi, P; Pistillo, P; Locati, L; Licitra, L
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma 1-gen-2006 Abou-Alfa, Gk; Schwartz, L; Ricci, S; Amadori, D; Santoro, A; Figer, A; De Greve, J; Douillard, Jy; Lathia, C; Schwartz, B; Taylor, I; Moscovici, M; Saltz, Lb
Mostrati risultati da 17.182 a 17.201 di 25.485
Legenda icone

  •  file ad accesso aperto
  •  file disponibili sulla rete interna
  •  file disponibili agli utenti autorizzati
  •  file disponibili solo agli amministratori
  •  file sotto embargo
  •  nessun file disponibile